Trilock® 4 mg OFT: Each oroflash tablet contains Montelukast Sodium USP 4.16 mg equivalent to Montelukast 4 mg.
Trilock® 5 mg OFT: Each oroflash tablet contains Montelukast Sodium USP 5.20 mg equivalent to Montelukast 5 mg.
Trilock® 4 mg Chewable Tablet: Each chewable tablet contains Montelukast Sodium USP 4.16 mg equivalent to Montelukast 4 mg.
Trilock® 5 mg Chewable Tablet: Each chewable tablet contains Montelukast Sodium USP 5.20 mg equivalent to Montelukast 5 mg.
Trilock® 10 mg Tablet: Each tablet contains Montelukast Sodium USP 10.40 mg equivalent to Montelukast 10 mg.
Trilock® 4 mg Oral Granules: Each sachet contains Montelukast sodium USP 4.15 mg equivalent to Montelukast 4 mg.
Indications: Montelukast (Trilock®) is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients. It is also indicated for the relief of symptoms of allergic rhinitis.
Montelukast (Trilock ) is a selective and orally active leukotriene receptor antagonist that blocks the leukotriene, receptor.
Mode of action:
The cysteinyl leukotriens (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriens receptors (CysLT1) found in human airway that are responsible in pathophysiology of asthma and other inflammatory process. Montelukast is a leukotriene receptor antagonist that inhibits the cysteinyl leukotriene; (CysLT1) receptor.
Montelukast (Trilock ) is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients. It is also indicated for the relief of symptoms of allergic rhinitis.
Generally montelukast doesn t causes drug interactions with other medications but clinical observation is important when co-administered with Phenobarbital and Rifampicin. Over dosage: There were no adverse experiences reported in the majority of overdosage reports. The frequent adverse experiences observed were thirst, mydriasis, hyperkinesias and abdominal pain, in the event of overdose, it is reasonable to employ the usual supportive measures e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.
Pregnancy: US-FDA approved pregnancy category B. Lactation: It is not known whether Montelukast is excreted in human milk. Caution should be exercised when Montelukast is given to a nursing mother.
Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks (in case of status asthmaticus). Patients with known aspirin sensitivity should continue avoidance of aspirin or other NSAID, while taking Montelukast.
Keep out of the reach of children. Store in a dry place, below 25 C temperature and protected from light.